Skip Navigation



Journal of the National Cancer Institute Advance Access published online on April 29, 2008
JNCI Journal of the National Cancer Institute, doi:10.1093/jnci/djn143
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
100/9/618    most recent
djn143v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Tuma, R. S.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tuma, R. S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2008.

NEWS

End of High-Dose Chemotherapy for High-Risk Breast Cancer Patients?

Rabiya S. Tuma

The first 10% of the full text of this article appears below.

High-dose chemotherapy does not improve overall survival in women with high-risk nonmetastatic breast cancer relative to standard chemotherapy, according to a meta-analysis presented last December at the San Antonio Breast Cancer Symposium. This is not the first meta-analysis to show that the approach does not improve breast cancer survival, but it could be the final one; many researchers hope it will end the period in breast cancer care in which opinions seemed to outweigh evidence. However, even with the new data, not everyone is ready to let go of high-dose chemotherapy just yet.

The idea behind the treatment is simple: If standard-dose cytotoxic chemotherapy kills some of the tumor cells, then . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?